REFERENCES:

ATAC Trialists’ Group. Pharmacokinetics of anastrozole and tamoxifen alone and in combination during adjuvant endocrine therapy for early breast can-cer in postmenopausal women: A sub-protocol of the “Arimidex® and Tamoxifen Alone or in Combination” (ATAC) trial. Br J Cancer 2001;85(3):317-324. Abstract

Baum M. The ATAC (Arimidex, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial in post-menopausal women. Breast Cancer Res Treat 2001;69(3): Abstract 8.

Boccardo F et al. Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: Results of an Italian cooperative study. J Clin Oncol 2001; 19: 4209 - 1 5 . Abstract

Demissie S et al. Adjuvant tamoxifen: Predictors of use, side effects, and discontinuation in older women. J Clin Oncol 2001;19:322-8. Abstract

Goss PE, Strasser K. Aromatase inhibitors in the treatment and prevention of breast cancer. J Clin Oncol 2001;19:881-94. Abstract

Hamilton A, Volm M. Nonsteroidal and steroidal aromatase inhibitors in breast cancer. Oncology (Huntingt) 2001;15:965-72; discussion 972, 977-9. Abstract

Harper-Wynne C, Dowsett M. Recent advances in the clinical application of aromatase inhibitors. J Steroid Biochem Mol Biol 2001;76:179-86. Abstract

Howell A et al. ICI 182,780 (Faslodex): Development of a novel, “pure” antiestrogen. Cancer 2000;89:817-25. Abstract

Ingle JN. Aromatase inhibition and antiestrogen therapy in early breast cancer treatment and chemoprevention. Oncology (Huntingt) 2001;15:28-34. Abstract

Knoop AS et al. Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients. J Clin Oncol 2001;19:3376-84. Abstract

Kuerer HM et al. Biologic basis and evolving role of aromatase inhibitors in the management of invasive carcinoma of the breast. J Surg Oncol 2001;77:139-47. Abstract

Mouridsen H et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol. 2001;19:2596-606. Abstract

Nabholtz JM et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multi-center randomized trial. J Clin Oncol 2000;18(22):3758-3767. Abstract

Osborne CK et al. Selective estrogen receptor modulators: Structure, function, and clinical use. J Clin Oncol 2000;18(17):3172-3186. Abstract

Stal O et al. ErbB2 status and the benefit from two or five years of adjuvant tamoxifen in postmenopausal early stage breast cancer. Ann Oncol 2000;11:1545-50. Abstract

Talvensaari-Mattila A et al. Matrix metalloproteinase-2 (MMP-2) is associated with the risk for a relapse in postmenopausal patients with node-positive breast carcinoma treated with antiestrogen adjuvant therapy. Breast Cancer Res Treat 2001;65:55-61. Abstract

Back | Top of Page